Jaguar Health Inc Stock Price, News & Analysis

Jaguar Health (NASDAQ:JAGX) said CEO Lisa Conte will present virtually at the Lytham Partners Healthcare Investor Summit on Thursday, January 15, 2026 at 3:30 PM ET. The presentation is virtual and open to registered attendees.

Investors can register via the conference registration link and a replay of the webcast will be available through the same link.

Jaguar Health (NASDAQ: JAGX) entered a U.S. license agreement with Future Pak on January 12, 2026, granting Future Pak exclusive U.S. marketing rights for Mytesi (crofelemer) and Canalevia-CA1 while Jaguar will remain the manufacturer.

Jaguar will receive an $18 million upfront payment ($16M at closing, $2M on post-closing conditions) and is eligible for up to $20 million in milestone and other future payments. The agreement includes a 12-month Jaguar right to reacquire rights for mutually agreed additional crofelemer indications upon U.S. regulatory approval. Jaguar said the deal provides non-dilutive capital to focus crofelemer development on rare-disease indications, with Phase 2 study results for MVID expected in March 2026.

Jaguar Health (NASDAQ:JAGX) highlighted an article (Dec 29, 2025) summarizing initial proof‑of‑concept results for crofelemer in pediatric intestinal failure patients in the UAE.

Key findings: parenteral support (PS) reductions ranged 12–37%—two SBS-IF patients showed 12.5–15.6% PS reduction at the highest dose over 12 weeks; one MVID patient showed up to 27% reduction over 12 weeks and up to 37% during an extension after reinitiation. Results also reported reduced loose watery stools.

The company notes PS has serious toxicities and crofelemer’s PS reductions may be disease‑modifying. Crofelemer holds Orphan Drug Designation from FDA and EMA; additional placebo‑controlled trials and an FDA meeting regarding an expedited pathway were also reported.

Jaguar Health (NASDAQ:JAGX) announced it received a $240,000 grant from the FDA Center for Veterinary Medicine on January 1, 2026 to support its Canalevia-CA1 effectiveness study for chemotherapy-induced diarrhea (CID) in dogs.

Canalevia-CA1 is conditionally approved for CID and the FDA renewed that conditional approval for a fifth and final year through December 21, 2026. Jaguar must complete and file a successful effectiveness study to obtain full veterinary drug approval for CID.

Jaguar Health (NASDAQ:JAGX) said an independent investigator submitted an abstract reporting preliminary clinical findings for a novel oral liquid formulation of crofelemer in adult short bowel syndrome with intestinal failure (SBS-IF); the abstract was submitted for consideration at Digestive Disease Week® May 2-5, 2026.

The release highlights prior independent trial results: crofelemer reduced parenteral support (PS) by 12–15.6% in two pediatric SBS-IF patients over 12 weeks, and by up to 27% (and up to 37% on extension) in an initial MVID patient. Jaguar completed an FDA meeting in October 2025 on a possible expedited pathway for MVID. Crofelemer holds Orphan Drug Designation in the US and EU for SBS and MVID.

Jaguar Health (NASDAQ:JAGX) announced the FDA renewed the conditional approval for Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced diarrhea (CID) in dogs, effective through December 21, 2026. The company said this renewal represents the fifth and final allowable year of conditional approval.

A confirmatory effectiveness trial is underway and is expected to conclude in February 2026, ahead of the FDA's June deadline; the study has enrolled 51 dogs to date with approximately 49 more expected. Canalevia-CA1 is available from multiple leading U.S. veterinary distributors, including Chewy.

Jaguar Health (NASDAQ:JAGX) reported that stockholders approved all three proposals at the Special Meeting held on December 8, 2025. The company highlighted early clinical and regulatory developments for crofelemer in microvillus inclusion disease (MVID): an investigator-initiated proof-of-concept trial showed crofelemer may extend infant lives and reduce total parenteral support (PS) volumes by up to 37%, though the report notes associated toxicity. Jaguar completed a meeting with the FDA on October 2, 2025 to seek advice on advancing its placebo-controlled crofelemer trial toward a possible expedited approval pathway. CEO Lisa Conte will present updates on December 10, 2025, 3:25–3:35 PM ET at the Emerging Growth Conference.

Jaguar Health (NASDAQ:JAGX) said its Italian unit submitted a request to the European Medicines Agency for CVMP scientific advice on pursuing EU approval of Canalevia (crofelemer) for general diarrhea in dogs based on a 2017 study of 200 dogs. The CVMP review is requested for its March 2026 meeting; EMA will have 60 days (extendable to 90) to respond. If EMA agrees the updated analysis supports approval, Jaguar would file a Marketing Authorization Application to sell Canalevia across the 27 EU member states. Jaguar also noted FDA conditional approval for chemotherapy-induced diarrhea in dogs and cited EU/US dog population and case estimates.

Jaguar Health (NASDAQ:JAGX) announced an Australian patent issued to Napo for methods treating short bowel syndrome (SBS), bile acid diarrhea, and post-resection diarrhea using an inhibitor of chloride-ion transport such as crofelemer (Nov 24, 2025).

Jaguar cited emerging proof-of-concept clinical data: two pediatric SBS-IF patients showed 12.5–15.6% reduction in parenteral support (PS) at 12 weeks; one MVID patient showed up to 27% reduction at 12 weeks and up to 37% on extension. Ongoing randomized trials and expanded access programs are active in US, EU, Middle East.